-
Something wrong with this record ?
Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade
I. Vaněčková, L. Řezáčová, J. Kuneš, J. Zicha,
Language English Country Netherlands
Document type Journal Article
Grant support
NV15-25396A
MZ0
CEP Register
- MeSH
- Endothelin Receptor Antagonists pharmacology MeSH
- Blood Pressure drug effects MeSH
- Rats MeSH
- Rats, Sprague-Dawley MeSH
- Rats, Transgenic MeSH
- Receptor, Endothelin A drug effects MeSH
- Renin-Angiotensin System drug effects MeSH
- Renin genetics physiology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
AIMS: Chronic endothelin receptor A (ETA) blockade lowered blood pressure (BP) by decreasing angiotensin-dependent vasoconstriction and attenuating calcium influx. We tested whether the addition of ETA blockade to renin-angiotensin system (RAS) blockade would have further effects on the principal vasoactive systems contributing to BP maintenance in Ren-2 transgenic rats (TGR). METHODS: Four-week-old TGR rats were fed with normal-salt diet and given either different renin-angiotensin system (RAS) blockers [angiotensin receptor blocker losartan, angiotensin converting enzyme inhibitor captopril, direct renin inhibitor aliskiren], or ETA blocker (atrasentan) alone, or a combination of atrasentan with RAS blockers for 4weeks. At the end of the study, basal BP and acute BP responses to sequential blockade of renin-angiotensin (RAS), sympathetic nervous (SNS), and nitric oxide (NO) systems were determined in conscious rats. Thereafter, BP responses to acute inhibition of nifedipine-sensitive calcium influx through voltage-dependent calcium channels (L-VDCC) were measured. KEY FINDINGS: All RAS blockers similarly decreased BP to normotension, their effects being mediated through substantially attenuated RAS-dependent and moderately decreased SNS-dependent vasoconstriction. Atrasentan alone partially lowered BP, while BP was normalized by combination of atrasentan with either RAS blocker. In combination therapies, BP lowering effects resulted from the attenuation of both RAS- and SNS-dependent vasoconstriction. Moreover, atrasentan-treated groups had substantially reduced NO-dependent vasodilation and significantly decreased calcium influx through L-VDCC. CONCLUSIONS: Although the BP-lowering effect of combined ETA and RAS blockades in TGR is predominantly dependent on the effects exerted by RAS blockade, further effects are attributable to decreased calcium influx due to chronic ETA blockade.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17014161
- 003
- CZ-PrNML
- 005
- 20170426113112.0
- 007
- ta
- 008
- 170413s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.lfs.2016.01.020 $2 doi
- 035 __
- $a (PubMed)26775568
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Vaněčková, Ivana $u Institute of Physiology AS CR, Prague, Czech Republic. Electronic address: ivanava@biomed.cas.cz.
- 245 10
- $a Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade / $c I. Vaněčková, L. Řezáčová, J. Kuneš, J. Zicha,
- 520 9_
- $a AIMS: Chronic endothelin receptor A (ETA) blockade lowered blood pressure (BP) by decreasing angiotensin-dependent vasoconstriction and attenuating calcium influx. We tested whether the addition of ETA blockade to renin-angiotensin system (RAS) blockade would have further effects on the principal vasoactive systems contributing to BP maintenance in Ren-2 transgenic rats (TGR). METHODS: Four-week-old TGR rats were fed with normal-salt diet and given either different renin-angiotensin system (RAS) blockers [angiotensin receptor blocker losartan, angiotensin converting enzyme inhibitor captopril, direct renin inhibitor aliskiren], or ETA blocker (atrasentan) alone, or a combination of atrasentan with RAS blockers for 4weeks. At the end of the study, basal BP and acute BP responses to sequential blockade of renin-angiotensin (RAS), sympathetic nervous (SNS), and nitric oxide (NO) systems were determined in conscious rats. Thereafter, BP responses to acute inhibition of nifedipine-sensitive calcium influx through voltage-dependent calcium channels (L-VDCC) were measured. KEY FINDINGS: All RAS blockers similarly decreased BP to normotension, their effects being mediated through substantially attenuated RAS-dependent and moderately decreased SNS-dependent vasoconstriction. Atrasentan alone partially lowered BP, while BP was normalized by combination of atrasentan with either RAS blocker. In combination therapies, BP lowering effects resulted from the attenuation of both RAS- and SNS-dependent vasoconstriction. Moreover, atrasentan-treated groups had substantially reduced NO-dependent vasodilation and significantly decreased calcium influx through L-VDCC. CONCLUSIONS: Although the BP-lowering effect of combined ETA and RAS blockades in TGR is predominantly dependent on the effects exerted by RAS blockade, further effects are attributable to decreased calcium influx due to chronic ETA blockade.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a krevní tlak $x účinky léků $7 D001794
- 650 _2
- $a antagonisté endotelinového receptoru $x farmakologie $7 D065128
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a potkani transgenní $7 D055647
- 650 _2
- $a receptor endotelinu A $x účinky léků $7 D044022
- 650 _2
- $a renin $x genetika $x fyziologie $7 D012083
- 650 _2
- $a renin-angiotensin systém $x účinky léků $7 D012084
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Řezáčová, Lenka $u Institute of Physiology AS CR, Prague, Czech Republic.
- 700 1_
- $a Kuneš, Jaroslav $u Institute of Physiology AS CR, Prague, Czech Republic.
- 700 1_
- $a Zicha, Josef $u Institute of Physiology AS CR, Prague, Czech Republic.
- 773 0_
- $w MED00003147 $t Life sciences $x 1879-0631 $g Roč. 159, č. - (2016), s. 127-34
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26775568 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170426113431 $b ABA008
- 999 __
- $a ok $b bmc $g 1200626 $s 974939
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 159 $c - $d 127-34 $e 20160114 $i 1879-0631 $m Life sciences $n Life Sci $x MED00003147
- GRA __
- $a NV15-25396A $p MZ0
- LZP __
- $a Pubmed-20170413